Cyfuse Biomedical K.K. (4892.T)
JPY 463.0
(2.89%)
JPY 463.0
(2.89%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 913 Million JPY | 0.53% |
| 2022 | 908.14 Million JPY | 59.59% |
| 2021 | 569.05 Million JPY | 7.46% |
| 2020 | 529.54 Million JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 808.5 Million JPY | -11.45% |
| 2024 Q2 | 804 Million JPY | -0.56% |
| 2023 Q3 | 819.72 Million JPY | -4.01% |
| 2023 FY | 913 Million JPY | 0.53% |
| 2023 Q4 | 913 Million JPY | 11.38% |
| 2023 Q2 | 854.01 Million JPY | -3.07% |
| 2023 Q1 | 881.07 Million JPY | -2.86% |
| 2022 FY | 908.14 Million JPY | 59.59% |
| 2022 Q4 | 907 Million JPY | 8.28% |
| 2022 Q3 | 837.64 Million JPY | 0.0% |
| 2021 FY | 569.05 Million JPY | 7.46% |
| 2020 FY | 529.54 Million JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 16.89 Billion JPY | 94.595% |
| Takeda Pharmaceutical Company Limited | 4843.75 Billion JPY | 99.981% |
| Sumitomo Pharma Co., Ltd. | 418.88 Billion JPY | 99.782% |
| Shionogi & Co., Ltd. | 11.62 Billion JPY | 92.143% |
| Wakamoto Pharmaceutical Co.,Ltd. | 100.52 Million JPY | -808.196% |
| Nippon Shinyaku Co., Ltd. | 2.87 Billion JPY | 68.21% |
| Kaken Pharmaceutical Co., Ltd. | 3.85 Billion JPY | 76.286% |
| Eisai Co., Ltd. | 206.74 Billion JPY | 99.558% |
| Morishita Jintan Co., Ltd. | 425 Million JPY | -114.824% |
| Hisamitsu Pharmaceutical Co., Inc. | 2.1 Billion JPY | 56.524% |
| Mochida Pharmaceutical Co., Ltd. | 369 Million JPY | -147.425% |
| Fuso Pharmaceutical Industries,Ltd. | 12.72 Billion JPY | 92.823% |
| Nippon Chemiphar Co., Ltd. | 16.98 Billion JPY | 94.623% |
| Tsumura & Co. | 79.69 Billion JPY | 98.854% |
| Kissei Pharmaceutical Co., Ltd. | 1.72 Billion JPY | 47.134% |
| Torii Pharmaceutical Co., Ltd. | 244 Million JPY | -274.18% |
| Towa Pharmaceutical Co., Ltd. | 202.35 Billion JPY | 99.549% |
| Fuji Pharma Co., Ltd. | 28.94 Billion JPY | 96.846% |
| Zeria Pharmaceutical Co., Ltd. | 47.58 Billion JPY | 98.081% |
| KYORIN Holdings, Inc. | 20.94 Billion JPY | 95.641% |
| Taiko Pharmaceutical Co.,Ltd. | 3.8 Billion JPY | 76.03% |
| Daito Pharmaceutical Co.,Ltd. | 8.71 Billion JPY | 89.529% |
| SymBio Pharmaceuticals Limited | - JPY | -Infinity% |
| MedRx Co., Ltd | - JPY | -Infinity% |
| Mizuho Medy Co.,Ltd. | - JPY | -Infinity% |
| Solasia Pharma K.K. | 60 Million JPY | -1421.667% |
| Modalis Therapeutics Corporation | 412.5 Million JPY | -121.333% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.48 Billion JPY | 90.374% |
| Sawai Group Holdings Co., Ltd. | 82.89 Billion JPY | 98.899% |
| Toho Holdings Co., Ltd. | 30.24 Billion JPY | 96.981% |
| Koa Shoji Holdings Co.,Ltd. | 2.82 Billion JPY | 67.685% |